Adam Glen & Jack Reid Founders Unicorn Biotechnologies In this interview, News-Medical speaks to Adam Glen and Jack Reid, founders of Unicorn Biotechnologies, about how their benchtop system Emmet is ...

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in ...

Biotech mogul Sam Waksal – who landed in prison two decades ago over the ImClone insider trading scandal that also resulted in jail time for Martha Stewart – allegedly tested an illegal ...

But today, Kendall has been reborn — as the glittering, glassy heart of America’s biotech industry ... the University itself faded into the background. Harvard’s Return But, ever so slowly ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

Mural Oncology is a biotechnology company that focuses on using its protein engineering platform to develop cytokine-based immunotherapies for cancer treatment. The company aims to deliver ...

China is moving fast to dominate biotechnology, and the U.S. risks falling behind permanently unless it takes action over the next three years, a congressional commission said. Congress should ...

A U.S. congressional commission has made the case for “swift action” to maintain the nation’s role as a biotech superpower, while warning the sector is “dangerously close to falling behind ...

AmplifyBio, once one of central Ohio's most promising biotech firms, announced Friday that it has shut down. In a posting on its website, the company said the decision followed months of efforts ...

The layoffs are scheduled for May 28. — Nkarta, a biotech company, 53 job cuts in South San Francisco. The downsizing occurred on March 31. The job cuts were all described as permanent ...

In this article, we will be taking a look at the 7 most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest ...

PORT-7 shows >90% tumor growth inhibition in mesothelioma models when combined with an anti-PD1 antibody. Portage plans a first-in-human trial for PORT-7 and aims to combine PORT-6 and PORT-7 to ...